Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Completes 1-For-15 Reverse Stock Split

NEW YORK – HTG Molecular has completed a 1-for-15 reverse stock split of its outstanding common stock.

As a result of the split, effective with the open of the market on Monday, the firm's common stock is now trading on a split-adjusted basis.

Authorization for the reverse split was approved by the firm's stockholders at HTG's annual stockholder meeting in August, and subsequently approved by its board of directors last week. The number of authorized shares of common stock will be reduced to 26.7 million from 200 million.

The reverse stock split combined 15 pre-split shares of HTG's common stock outstanding into one share. The firm has not issued any fractional shares and is instead paying cash to stockholders with remaining fractional shares.  

In October 2019, Tucson, Arizona-based HTG received a notice of non-compliance Nasdaq indicating that it had failed to meet a listing requirement calling for a minimum closing bid of $1 per share.

HTG's stock was down about 2 percent at $4.19 in early-morning trading.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.